1064706-98-4 Usage
Uses
1. Used in Pharmaceutical Industry:
[1-(4-[(4-fluorobenzyl)amino]carbonyl-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1-methylethyl]amino(oxo)acetic acid is used as a building block for the synthesis of novel pharmaceutical compounds. Its unique structure and functional groups can be exploited to create new drugs with specific therapeutic properties.
2. Used in Chemical Research:
[1-(4-[(4-fluorobenzyl)amino]carbonyl-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1-methylethyl]amino(oxo)acetic acid serves as a valuable compound for chemical research and development. It can be used to study various reaction mechanisms and to develop new synthetic methods for complex organic molecules.
3. Used in Material Science:
[1-(4-[(4-fluorobenzyl)amino]carbonyl-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1-methylethyl]amino(oxo)acetic acid may have potential applications in the development of new materials with specific properties, such as improved stability, reactivity, or selectivity in various chemical processes.
4. Used in Drug Delivery Systems:
Similar to the use of gallotannin in drug delivery systems, [1-(4-[(4-fluorobenzyl)amino]carbonyl-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-1-methylethyl]amino(oxo)acetic acid could be utilized in the development of innovative drug delivery systems. Its unique structure and functional groups may allow for the creation of targeted drug carriers, improving the bioavailability and therapeutic outcomes of various pharmaceutical compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 1064706-98-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,4,7,0 and 6 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1064706-98:
(9*1)+(8*0)+(7*6)+(6*4)+(5*7)+(4*0)+(3*6)+(2*9)+(1*8)=154
154 % 10 = 4
So 1064706-98-4 is a valid CAS Registry Number.
1064706-98-4Relevant academic research and scientific papers
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection
Summa, Vincenzo,Petrocchi, Alessia,Bonelli, Fabio,Crescenzi, Benedetta,Donghi, Monica,Ferrara, Marco,Fiore, Fabrizio,Gardelli, Cristina,Paz, Odalys Gonzalez,Hazuda, Daria J.,Jones, Philip,Kinzel, Olaf,Laufer, Ralph,Monteagudo, Edith,Muraglia, Ester,Nizi, Emanuela,Orvieto, Federica,Pace, Paola,Pescatore, Giovanna,Scarpelli, Rita,Stillmock, Kara,Witmer, Marc V.,Rowley, Michael
experimental part, p. 5843 - 5855 (2009/09/25)
Human immunodeficiency virus type-1 (HIV-1) integrase is one of the three virally encoded enzymes required for replication and therefore a rational target for chemotherapeutic intervention in the treatment of HIV-1 infection. We report here the discovery of Raltegravir, the first HIV-integrase inhibitor approved by FDA for the treatment of HIV infection. It derives from the evolution of 5,6-dihydroxypyrimidine-4-carboxamides and N-methyl-4- hydroxypyrimidinone-carboxamides, which exhibited potent inhibition of the HIV-integrase catalyzed strand transfer process. Structural modifications on these molecules were made in order to maximize potency as HIV-integrase inhibitors against the wild type virus, a selection of mutants, and optimize the selectivity, pharmacokinetic, and metabolic profiles in preclinical species. The good profile of Raltegravir has enabled its progression toward the end of phase III clinical trials for the treatment of HIV-1 infection and culminated with the FDA approval as the first HIV-integrase inhibitor for the treatment of HIV-1 infection.
